Florian Rensch Jost B.Jonas Ulrich H.M.Spandau
Department of Ophthalmology，Medical Faculty Mannheim of the Ruprecht-Karls-University Heidelberg，Germany
100005
Purpose:To evaluate the effect of early intravitreal bevacizumab injections in patients with non-ischemic central retinal vein occlusion(CRVO).Methods.The study included 25 patients(25 eyes)with macular edema due to non-ischemic CRVO，who received three intravitreal injections of 1.5 mg bevacizumab with an interval of six weeks between the injections.Mean duration of central retinal vein occlusion prior to the first injection was 4.2±3.6 days.Results.Mean visual acuity improved significantly from 0.97±0.40 logMAR at baseline to 0.70±0.42(P=0.007)at 1 month;to 0.69±0.46(P=0.006)at 3 months，and to 0.69±0.52(P=0.015)at 6 months after the first injection.Mean central retinal thickness decreased significantly from 530±152 μm at baseline to 347±127 μm(p<0.001)at one month;to 370±165 μm(p<0.001)at 3 months;and to 346±129 μm(P<0.001)at 6 months(p<0.001)after the first injection.Conclusions.Intravitreal bevacizumab injections given shortly after onset of non-ischemic CRVO may result in a significant increase in vision and a corresponding decrease in macular edema. |
